189 related articles for article (PubMed ID: 34455369)
21. Polycomb-dependent epigenetic landscape in adult T-cell leukemia.
Fujikawa D; Nakagawa S; Hori M; Kurokawa N; Soejima A; Nakano K; Yamochi T; Nakashima M; Kobayashi S; Tanaka Y; Iwanaga M; Utsunomiya A; Uchimaru K; Yamagishi M; Watanabe T
Blood; 2016 Apr; 127(14):1790-802. PubMed ID: 26773042
[TBL] [Abstract][Full Text] [Related]
22. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
Li S; Pal R; Monaghan SA; Schafer P; Ouyang H; Mapara M; Galson DL; Lentzsch S
Blood; 2011 May; 117(19):5157-65. PubMed ID: 21389327
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Kuwahara-Ota S; Shimura Y; Steinebach C; Isa R; Yamaguchi J; Nishiyama D; Fujibayashi Y; Takimoto-Shimomura T; Mizuno Y; Matsumura-Kimoto Y; Tsukamoto T; Chinen Y; Kobayashi T; Horiike S; Taniwaki M; Gütschow M; Kuroda J
Br J Haematol; 2020 Dec; 191(5):784-795. PubMed ID: 32558939
[TBL] [Abstract][Full Text] [Related]
24. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Kastritis E; Roussou M; Gavriatopoulou M; Kanellias N; Migkou M; Eleutherakis-Papaiakovou E; Ziogas DC; Fotiou D; Ntanasis-Stathopoulos I; Dialoupi I; Giannouli S; Tsirigotis P; Delimpasi S; Mparmparousi D; Spyropoulou-Vlachou M; Xirokosta A; Terpos E; Dimopoulos MA
Blood Adv; 2019 Dec; 3(23):4095-4103. PubMed ID: 31821457
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Eichner R; Heider M; Fernández-Sáiz V; van Bebber F; Garz AK; Lemeer S; Rudelius M; Targosz BS; Jacobs L; Knorn AM; Slawska J; Platzbecker U; Germing U; Langer C; Knop S; Einsele H; Peschel C; Haass C; Keller U; Schmid B; Götze KS; Kuster B; Bassermann F
Nat Med; 2016 Jul; 22(7):735-43. PubMed ID: 27294876
[TBL] [Abstract][Full Text] [Related]
26. The regulation of NDRG2 expression during ATLL development after HTLV-1 infection.
Ichikawa T; Nakahata S; Fujii M; Iha H; Shimoda K; Morishita K
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2633-2646. PubMed ID: 31295529
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol suppresses cell proliferation via inhibition of STAT3 phosphorylation and Mcl-1 and cIAP-2 expression in HTLV-1-infected T cells.
Suzuki Y; Ito S; Sasaki R; Asahi M; Ishida Y
Leuk Res; 2013 Dec; 37(12):1674-9. PubMed ID: 24090995
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
North BJ; Almeciga-Pinto I; Tamang D; Yang M; Jones SS; Quayle SN
PLoS One; 2017; 12(3):e0173507. PubMed ID: 28264055
[TBL] [Abstract][Full Text] [Related]
30. IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways.
Sawada L; Nagano Y; Hasegawa A; Kanai H; Nogami K; Ito S; Sato T; Yamano Y; Tanaka Y; Masuda T; Kannagi M
PLoS Pathog; 2017 Sep; 13(9):e1006597. PubMed ID: 28910419
[TBL] [Abstract][Full Text] [Related]
31. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
[TBL] [Abstract][Full Text] [Related]
32. Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Kurahashi Y; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Yamashita S; Hattori N; Nakamura H; Kawaguchi A; Ushijima T; Sueoka E; Kimura S
Blood Adv; 2023 Apr; 7(8):1545-1559. PubMed ID: 36516085
[TBL] [Abstract][Full Text] [Related]
33. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
[TBL] [Abstract][Full Text] [Related]
34. HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Won HR; Lee DH; Yeon SK; Ryu HW; Kim GW; Kwon SH
Int J Oncol; 2019 Aug; 55(2):499-512. PubMed ID: 31268156
[TBL] [Abstract][Full Text] [Related]
35. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
36. IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
Suzuki K; Yano S
Life (Basel); 2023 Nov; 13(11):. PubMed ID: 38004369
[TBL] [Abstract][Full Text] [Related]
37. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
38. Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells.
Kinpara S; Kijiyama M; Takamori A; Hasegawa A; Sasada A; Masuda T; Tanaka Y; Utsunomiya A; Kannagi M
Retrovirology; 2013 May; 10():52. PubMed ID: 23688327
[TBL] [Abstract][Full Text] [Related]
39. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of EZH2 (Enhancer of Zeste Homolog 2) Attenuates Neuroinflammation via H3k27me3/SOCS3/TRAF6/NF-κB (Trimethylation of Histone 3 Lysine 27/Suppressor of Cytokine Signaling 3/Tumor Necrosis Factor Receptor Family 6/Nuclear Factor-κB) in a Rat Model of Subarachnoid Hemorrhage.
Luo Y; Fang Y; Kang R; Lenahan C; Gamdzyk M; Zhang Z; Okada T; Tang J; Chen S; Zhang JH
Stroke; 2020 Nov; 51(11):3320-3331. PubMed ID: 32933418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
